fter a rollicking August sent the Nasdaq biotech index to its highest value since late 2015, the industry is now barreling into a September brimming with major binary events that could either wreck the rally or reinstate the boom.
We figured that called for a scorecard.
We already know Otonomy bombed out with its big late-stage effort in Ménière’s disease, and we know Novartis won a pioneering — and ahead-of-schedule — FDA approval with a CAR-T for blood cancer.
There’s a lot more to come. We’ll be updating the card all month as data roll in, so stay tuned.
And for more on the results, check out the coverage in STAT Plus.